AbbVie stock is trading 12.6% below analyst fair value estimates after releasing nine-year final results from its CLL14 cancer trial, but faces a valuation puzzle as its P/E ratio signals investors are paying a steep premium for earnings growth.

What happened

AbbVie released nine year final results from its Phase 3 CLL14 trial, where a fixed duration venetoclax plus obinutuzumab regimen improved progression free survival in untreated CLL (chronic lymphocytic leukemia) patients. The stock is trading at $221.59, against an analyst fair value of $253.55.

Why it matters

Analysts believe AbbVie is undervalued because robust growth in immunology drugs Skyrizi and Rinvoq, driven by expanded use across indications like inflammatory bowel disease and dermatology, should sustain revenue growth and offset the impact of Humira losing patent protection. However, the company faces concentrated exposure to a small group of immunology and neuroscience drugs, along with pressure from tighter global drug pricing.

What to watch

AbbVie's current P/E ratio of 108.9x sits well above the fair value ratio of 37.4x and the US biotech average of 16.4x, signaling that investors are accepting higher valuation risk for the earnings profile being modeled. The gap raises a question about whether the recent pullback reflects a genuine buying opportunity or if the market is already pricing in the forecast growth.